Aveo Signs J&J As Partner In Early-Stage RON Antibody Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Given the early-stage nature of the collaboration, Aveo will receive $15 million upfront for preclinical antibodies targeting the RON receptor.
You may also be interested in...
How Biologics Are Powering J&J’s Resurgent Drug Business: An Interview with Jay Siegel
After well-publicized problems in Johnson & Johnson’s devices and consumer health divisions, in the words of a recent Deutsche Bank research note, “It’s pharmaceuticals’ time to shine.” Indeed, the diversified health care company expects to file 11 new drugs and over 31 line extensions by 2015. Though growth is now expected from J&J’s pharma business, less well understood is the role of biologics, both marketed and near to market, in driving that expansion and J&J’s increased focus on specialty products.
How Biologics Are Powering J&J’s Resurgent Drug Business: An Interview with Jay Siegel
After well-publicized problems in Johnson & Johnson’s devices and consumer health divisions, in the words of a recent Deutsche Bank research note, “It’s pharmaceuticals’ time to shine.” Indeed, the diversified health care company expects to file 11 new drugs and over 31 line extensions by 2015. Though growth is now expected from J&J’s pharma business, less well understood is the role of biologics, both marketed and near to market, in driving that expansion and J&J’s increased focus on specialty products.
Merrimack Files S-1, But Life-Science IPO Market Far From Ironclad
The cancer drug maker aims to raise as much as $172.5 million and bring liquidity to investors who have poured in more than $250 million.